Sandoz

Sandoz Group AG
Formerly	Sandoz GmbH
Company type	Public (Aktiengesellschaft)
Traded as	SIX: SDZ; SMI MID component;
ISIN	CH1243598427
Industry	Biosimilars; Generics; Biopharmaceuticals;
Predecessor	Ciba-Geigy
Founded	1886
Founder	Alfred Kern; Edouard Sandoz;
Headquarters	Basel, Switzerland
Key people	Richard Saynor (CEO); Francisco Ballester (President International); Gilbert Ghostine (Chairman);
Revenue	US$9.647 billion (2023)
Operating income	US$375 million (2023)
Net income	US$953 million (2023)
Total assets	US$19.430 billion (2023)
Total equity	US$8.654 billion (2023)
Number of employees	23,848 (2023)
Website	sandoz.com
	Footnotes / references;

Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars.^[4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics businesses.^[5]^[6]

^ ^a ^b ^c "Sandoz reports fourth quarter 2023 sales and full-year 2023 results". Sandoz. March 13, 2024. Archived from the original on March 13, 2024. Retrieved March 13, 2024.
^ ^a ^b ^c ^d ^e "2023 Integrated Annual Report" (PDF). Sandoz. March 13, 2024. Archived (PDF) from the original on March 13, 2024. Retrieved March 13, 2024.
^ "Novartis continues to grow with further core margin expansion and achieves important innovation milestones". Sandoz. February 2023. Archived from the original on July 5, 2023. Retrieved July 4, 2023.
^ "Contact Sandoz". www.sandoz.com. Archived from the original on 2023-11-28. Retrieved 2023-10-04.
^ "Live. Magazine". live.novartis.com. Archived from the original on 2023-10-04. Retrieved 2023-07-05.
^ Grover, Natalie (2023-06-08). "Novartis' Sandoz wagers its standalone future on biosimilar success". Reuters. Archived from the original on 2023-07-05. Retrieved 2023-07-05.

[annual-report2023-1] "Sandoz reports fourth quarter 2023 sales and full-year 2023 results". Sandoz. March 13, 2024. Archived from the original on March 13, 2024. Retrieved March 13, 2024.

[integrated-annual-report2023-2] "2023 Integrated Annual Report" (PDF). Sandoz. March 13, 2024. Archived (PDF) from the original on March 13, 2024. Retrieved March 13, 2024.

[annual-report-3] "Novartis continues to grow with further core margin expansion and achieves important innovation milestones". Sandoz. February 2023. Archived from the original on July 5, 2023. Retrieved July 4, 2023.

[4] "Contact Sandoz". www.sandoz.com. Archived from the original on 2023-11-28. Retrieved 2023-10-04.

[Live._Magazine-5] "Live. Magazine". live.novartis.com. Archived from the original on 2023-10-04. Retrieved 2023-07-05.

[6] Grover, Natalie (2023-06-08). "Novartis' Sandoz wagers its standalone future on biosimilar success". Reuters. Archived from the original on 2023-07-05. Retrieved 2023-07-05.

[1]

[2]

[3]

[4]

[5]

[6]